All In Biotech

Drug Trial Radar · NCT07875933

Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Non-inferiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 414 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

414

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Sep 6, 2028

Study completion Oct 6, 2028

Sponsor

Lead sponsor
Onconic Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the Efficacy and Safety of JP-1366-based Triple-Therapy in H. pylori-positive Subjects

Conditions

  • H. Pylori Eradication Therapy

Interventions

  • JP-1366 20 mg, Lansoprazole 30 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mgDrug

    Orally, twice daily

  • Lansoprazole 30mg, JP-1366 20 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mgDrug

    Orally, twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. H. pylori eradication rate after a minimum of 4 weeks from completion of Investigational product administrationTime frame: at least 4 weeks after completion of administration

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.